High-risk human papillomavirus status and prognosis in invasive cervical cancer: A nationwide cohort study
High-risk human papillomavirus (hrHPV) infection is established as the major cause of invasive cervical cancer (ICC). However, whether hrHPV status in the tumor is associated with subsequent prognosis of ICC is controversial. We aim to evaluate the association between tumor hrHPV status and ICC prog...
Saved in:
Published in | PLoS medicine Vol. 15; no. 10; p. e1002666 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Public Library of Science
01.10.2018
Public Library of Science (PLoS) |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | High-risk human papillomavirus (hrHPV) infection is established as the major cause of invasive cervical cancer (ICC). However, whether hrHPV status in the tumor is associated with subsequent prognosis of ICC is controversial. We aim to evaluate the association between tumor hrHPV status and ICC prognosis using national registers and comprehensive human papillomavirus (HPV) genotyping.
In this nationwide population-based cohort study, we identified all ICC diagnosed in Sweden during the years 2002-2011 (4,254 confirmed cases), requested all archival formalin-fixed paraffin-embedded blocks, and performed HPV genotyping. Twenty out of 25 pathology biobanks agreed to the study, yielding a total of 2,845 confirmed cases with valid HPV results. Cases were prospectively followed up from date of cancer diagnosis to 31 December 2015, migration from Sweden, or death, whichever occurred first. The main exposure was tumor hrHPV status classified as hrHPV-positive and hrHPV-negative. The primary outcome was all-cause mortality by 31 December 2015. Five-year relative survival ratios (RSRs) were calculated, and excess hazard ratios (EHRs) with 95% confidence intervals (CIs) were estimated using Poisson regression, adjusting for education, time since cancer diagnosis, and clinical factors including age at cancer diagnosis and International Federation of Gynecology and Obstetrics (FIGO) stage. Of the 2,845 included cases, hrHPV was detected in 2,293 (80.6%), and we observed 1,131 (39.8%) deaths during an average of 6.2 years follow-up. The majority of ICC cases were diagnosed at age 30-59 years (57.5%) and classified as stage IB (40.7%). hrHPV positivity was significantly associated with screen-detected tumors, young age, high education level, and early stage at diagnosis (p < 0.001). The 5-year RSR compared to the general female population was 0.74 (95% CI 0.72-0.76) for hrHPV-positive cases and 0.54 (95% CI 0.50-0.59) for hrHPV-negative cases, yielding a crude EHR of 0.45 (95% CI 0.38-0.52) and an adjusted EHR of 0.61 (95% CI 0.52-0.71). Risk of all-cause mortality as measured by EHR was consistently and statistically significantly lower for cases with hrHPV-positive tumors for each age group above 29 years and each FIGO stage above IA. The difference in prognosis by hrHPV status was highly robust, regardless of the clinical, histological, and educational characteristics of the cases. The main limitation was that, except for education, we were not able to adjust for lifestyle factors or other unmeasured confounders.
In this study, women with hrHPV-positive cervical tumors had a substantially better prognosis than women with hrHPV-negative tumors. hrHPV appears to be a biomarker for better prognosis in cervical cancer independent of age, FIGO stage, and histological type, extending information from already established prognostic factors. The underlying biological mechanisms relating lack of detectable tumor hrHPV to considerably worse prognosis are not known and should be further investigated. |
---|---|
AbstractList | In a study of Swedish medical records and tissue archives, Jiayao Lei and colleagues examine the link between hrHPV positivity in cervical tumors and prognosis. BackgroundHigh-risk human papillomavirus (hrHPV) infection is established as the major cause of invasive cervical cancer (ICC). However, whether hrHPV status in the tumor is associated with subsequent prognosis of ICC is controversial. We aim to evaluate the association between tumor hrHPV status and ICC prognosis using national registers and comprehensive human papillomavirus (HPV) genotyping.Methods and findingsIn this nationwide population-based cohort study, we identified all ICC diagnosed in Sweden during the years 2002-2011 (4,254 confirmed cases), requested all archival formalin-fixed paraffin-embedded blocks, and performed HPV genotyping. Twenty out of 25 pathology biobanks agreed to the study, yielding a total of 2,845 confirmed cases with valid HPV results. Cases were prospectively followed up from date of cancer diagnosis to 31 December 2015, migration from Sweden, or death, whichever occurred first. The main exposure was tumor hrHPV status classified as hrHPV-positive and hrHPV-negative. The primary outcome was all-cause mortality by 31 December 2015. Five-year relative survival ratios (RSRs) were calculated, and excess hazard ratios (EHRs) with 95% confidence intervals (CIs) were estimated using Poisson regression, adjusting for education, time since cancer diagnosis, and clinical factors including age at cancer diagnosis and International Federation of Gynecology and Obstetrics (FIGO) stage. Of the 2,845 included cases, hrHPV was detected in 2,293 (80.6%), and we observed 1,131 (39.8%) deaths during an average of 6.2 years follow-up. The majority of ICC cases were diagnosed at age 30-59 years (57.5%) and classified as stage IB (40.7%). hrHPV positivity was significantly associated with screen-detected tumors, young age, high education level, and early stage at diagnosis (p < 0.001). The 5-year RSR compared to the general female population was 0.74 (95% CI 0.72-0.76) for hrHPV-positive cases and 0.54 (95% CI 0.50-0.59) for hrHPV-negative cases, yielding a crude EHR of 0.45 (95% CI 0.38-0.52) and an adjusted EHR of 0.61 (95% CI 0.52-0.71). Risk of all-cause mortality as measured by EHR was consistently and statistically significantly lower for cases with hrHPV-positive tumors for each age group above 29 years and each FIGO stage above IA. The difference in prognosis by hrHPV status was highly robust, regardless of the clinical, histological, and educational characteristics of the cases. The main limitation was that, except for education, we were not able to adjust for lifestyle factors or other unmeasured confounders.ConclusionsIn this study, women with hrHPV-positive cervical tumors had a substantially better prognosis than women with hrHPV-negative tumors. hrHPV appears to be a biomarker for better prognosis in cervical cancer independent of age, FIGO stage, and histological type, extending information from already established prognostic factors. The underlying biological mechanisms relating lack of detectable tumor hrHPV to considerably worse prognosis are not known and should be further investigated. Background High-risk human papillomavirus (hrHPV) infection is established as the major cause of invasive cervical cancer (ICC). However, whether hrHPV status in the tumor is associated with subsequent prognosis of ICC is controversial. We aim to evaluate the association between tumor hrHPV status and ICC prognosis using national registers and comprehensive human papillomavirus (HPV) genotyping. Methods and findings In this nationwide population-based cohort study, we identified all ICC diagnosed in Sweden during the years 2002–2011 (4,254 confirmed cases), requested all archival formalin-fixed paraffin-embedded blocks, and performed HPV genotyping. Twenty out of 25 pathology biobanks agreed to the study, yielding a total of 2,845 confirmed cases with valid HPV results. Cases were prospectively followed up from date of cancer diagnosis to 31 December 2015, migration from Sweden, or death, whichever occurred first. The main exposure was tumor hrHPV status classified as hrHPV-positive and hrHPV-negative. The primary outcome was all-cause mortality by 31 December 2015. Five-year relative survival ratios (RSRs) were calculated, and excess hazard ratios (EHRs) with 95% confidence intervals (CIs) were estimated using Poisson regression, adjusting for education, time since cancer diagnosis, and clinical factors including age at cancer diagnosis and International Federation of Gynecology and Obstetrics (FIGO) stage. Of the 2,845 included cases, hrHPV was detected in 2,293 (80.6%), and we observed 1,131 (39.8%) deaths during an average of 6.2 years follow-up. The majority of ICC cases were diagnosed at age 30–59 years (57.5%) and classified as stage IB (40.7%). hrHPV positivity was significantly associated with screen-detected tumors, young age, high education level, and early stage at diagnosis (p < 0.001). The 5-year RSR compared to the general female population was 0.74 (95% CI 0.72–0.76) for hrHPV-positive cases and 0.54 (95% CI 0.50–0.59) for hrHPV-negative cases, yielding a crude EHR of 0.45 (95% CI 0.38–0.52) and an adjusted EHR of 0.61 (95% CI 0.52–0.71). Risk of all-cause mortality as measured by EHR was consistently and statistically significantly lower for cases with hrHPV-positive tumors for each age group above 29 years and each FIGO stage above IA. The difference in prognosis by hrHPV status was highly robust, regardless of the clinical, histological, and educational characteristics of the cases. The main limitation was that, except for education, we were not able to adjust for lifestyle factors or other unmeasured confounders. Conclusions In this study, women with hrHPV-positive cervical tumors had a substantially better prognosis than women with hrHPV-negative tumors. hrHPV appears to be a biomarker for better prognosis in cervical cancer independent of age, FIGO stage, and histological type, extending information from already established prognostic factors. The underlying biological mechanisms relating lack of detectable tumor hrHPV to considerably worse prognosis are not known and should be further investigated. High-risk human papillomavirus (hrHPV) infection is established as the major cause of invasive cervical cancer (ICC). However, whether hrHPV status in the tumor is associated with subsequent prognosis of ICC is controversial. We aim to evaluate the association between tumor hrHPV status and ICC prognosis using national registers and comprehensive human papillomavirus (HPV) genotyping. In this nationwide population-based cohort study, we identified all ICC diagnosed in Sweden during the years 2002-2011 (4,254 confirmed cases), requested all archival formalin-fixed paraffin-embedded blocks, and performed HPV genotyping. Twenty out of 25 pathology biobanks agreed to the study, yielding a total of 2,845 confirmed cases with valid HPV results. Cases were prospectively followed up from date of cancer diagnosis to 31 December 2015, migration from Sweden, or death, whichever occurred first. The main exposure was tumor hrHPV status classified as hrHPV-positive and hrHPV-negative. The primary outcome was all-cause mortality by 31 December 2015. Five-year relative survival ratios (RSRs) were calculated, and excess hazard ratios (EHRs) with 95% confidence intervals (CIs) were estimated using Poisson regression, adjusting for education, time since cancer diagnosis, and clinical factors including age at cancer diagnosis and International Federation of Gynecology and Obstetrics (FIGO) stage. Of the 2,845 included cases, hrHPV was detected in 2,293 (80.6%), and we observed 1,131 (39.8%) deaths during an average of 6.2 years follow-up. The majority of ICC cases were diagnosed at age 30-59 years (57.5%) and classified as stage IB (40.7%). hrHPV positivity was significantly associated with screen-detected tumors, young age, high education level, and early stage at diagnosis (p < 0.001). The 5-year RSR compared to the general female population was 0.74 (95% CI 0.72-0.76) for hrHPV-positive cases and 0.54 (95% CI 0.50-0.59) for hrHPV-negative cases, yielding a crude EHR of 0.45 (95% CI 0.38-0.52) and an adjusted EHR of 0.61 (95% CI 0.52-0.71). Risk of all-cause mortality as measured by EHR was consistently and statistically significantly lower for cases with hrHPV-positive tumors for each age group above 29 years and each FIGO stage above IA. The difference in prognosis by hrHPV status was highly robust, regardless of the clinical, histological, and educational characteristics of the cases. The main limitation was that, except for education, we were not able to adjust for lifestyle factors or other unmeasured confounders. In this study, women with hrHPV-positive cervical tumors had a substantially better prognosis than women with hrHPV-negative tumors. hrHPV appears to be a biomarker for better prognosis in cervical cancer independent of age, FIGO stage, and histological type, extending information from already established prognostic factors. The underlying biological mechanisms relating lack of detectable tumor hrHPV to considerably worse prognosis are not known and should be further investigated. Background: High-risk human papillomavirus (hrHPV) infection is established as the major cause of invasive cervical cancer (ICC). However, whether hrHPV status in the tumor is associated with subsequent prognosis of ICC is controversial. We aim to evaluate the association between tumor hrHPV status and ICC prognosis using national registers and comprehensive human papillomavirus (HPV) genotyping. Methods and findings: In this nationwide population-based cohort study, we identified all ICC diagnosed in Sweden during the years 2002-2011 (4,254 confirmed cases), requested all archival formalin-fixed paraffin-embedded blocks, and performed HPV genotyping. Twenty out of 25 pathology bio-banks agreed to the study, yielding a total of 2,845 confirmed cases with valid HPV results. Cases were prospectively followed up from date of cancer diagnosis to 31 December 2015, migration from Sweden, or death, whichever occurred first. The main exposure was tumor hrHPV status classified as hrHPV-positive and hrHPV-negative. The primary outcome was all-cause mortality by 31 December 2015. Five-year relative survival ratios (RSRs) were calculated, and excess hazard ratios (EHRs) with 95% confidence intervals (CIs) were estimated using Poisson regression, adjusting for education, time since cancer diagnosis, and clinical factors including age at cancer diagnosis and International Federation of Gynecology and Obstetrics (FIGO) stage. Of the 2,845 included cases, hrHPV was detected in 2,293 (80.6%), and we observed 1,131 (39.8%) deaths during an average of 6.2 years follow-up. The majority of ICC cases were diagnosed at age 30-59 years (57.5%) and classified as stage IB (40.7%). hrHPV positivity was significantly associated with screen-detected tumors, young age, high education level, and early stage at diagnosis (p < 0.001). The 5-year RSR compared to the general female population was 0.74 (95% CI 0.72-0.76) for hrHPV-positive cases and 0.54 (95% CI 0.50-0.59) for hrHPV-negative cases, yielding a crude EHR of 0.45 (95% CI 0.38-0.52) and an adjusted EHR of 0.61 (95% CI 0.52-0.71). Risk of all-cause mortality as measured by EHR was consistently and statistically significantly lower for cases with hrHPV-positive tumors for each age group above 29 years and each FIGO stage above IA. The difference in prognosis by hrHPV status was highly robust, regardless of the clinical, histological, and educational characteristics of the cases. The main limitation was that, except for education, we were not able to adjust for lifestyle factors or other unmeasured confounders. Conclusions: In this study, women with hrHPV-positive cervical tumors had a substantially better prognosis than women with hrHPV-negative tumors. hrHPV appears to be a biomarker for better prognosis in cervical cancer independent of age, FIGO stage, and histological type, extending information from already established prognostic factors. The underlying biological mechanisms relating lack of detectable tumor hrHPV to considerably worse prognosis are not known and should be further investigated. Background High-risk human papillomavirus (hrHPV) infection is established as the major cause of invasive cervical cancer (ICC). However, whether hrHPV status in the tumor is associated with subsequent prognosis of ICC is controversial. We aim to evaluate the association between tumor hrHPV status and ICC prognosis using national registers and comprehensive human papillomavirus (HPV) genotyping. Methods and findings In this nationwide population-based cohort study, we identified all ICC diagnosed in Sweden during the years 2002–2011 (4,254 confirmed cases), requested all archival formalin-fixed paraffin-embedded blocks, and performed HPV genotyping. Twenty out of 25 pathology biobanks agreed to the study, yielding a total of 2,845 confirmed cases with valid HPV results. Cases were prospectively followed up from date of cancer diagnosis to 31 December 2015, migration from Sweden, or death, whichever occurred first. The main exposure was tumor hrHPV status classified as hrHPV-positive and hrHPV-negative. The primary outcome was all-cause mortality by 31 December 2015. Five-year relative survival ratios (RSRs) were calculated, and excess hazard ratios (EHRs) with 95% confidence intervals (CIs) were estimated using Poisson regression, adjusting for education, time since cancer diagnosis, and clinical factors including age at cancer diagnosis and International Federation of Gynecology and Obstetrics (FIGO) stage. Of the 2,845 included cases, hrHPV was detected in 2,293 (80.6%), and we observed 1,131 (39.8%) deaths during an average of 6.2 years follow-up. The majority of ICC cases were diagnosed at age 30–59 years (57.5%) and classified as stage IB (40.7%). hrHPV positivity was significantly associated with screen-detected tumors, young age, high education level, and early stage at diagnosis (p < 0.001). The 5-year RSR compared to the general female population was 0.74 (95% CI 0.72–0.76) for hrHPV-positive cases and 0.54 (95% CI 0.50–0.59) for hrHPV-negative cases, yielding a crude EHR of 0.45 (95% CI 0.38–0.52) and an adjusted EHR of 0.61 (95% CI 0.52–0.71). Risk of all-cause mortality as measured by EHR was consistently and statistically significantly lower for cases with hrHPV-positive tumors for each age group above 29 years and each FIGO stage above IA. The difference in prognosis by hrHPV status was highly robust, regardless of the clinical, histological, and educational characteristics of the cases. The main limitation was that, except for education, we were not able to adjust for lifestyle factors or other unmeasured confounders. Conclusions In this study, women with hrHPV-positive cervical tumors had a substantially better prognosis than women with hrHPV-negative tumors. hrHPV appears to be a biomarker for better prognosis in cervical cancer independent of age, FIGO stage, and histological type, extending information from already established prognostic factors. The underlying biological mechanisms relating lack of detectable tumor hrHPV to considerably worse prognosis are not known and should be further investigated. |
Author | Lagheden, Camilla Nordqvist Kleppe, Sara Andrae, Bengt Sundström, Karin Elfström, K Miriam Dillner, Joakim Ploner, Alexander Eklund, Carina Lei, Jiayao Sparén, Pär |
AuthorAffiliation | Vanderbilt University School of Medicine, UNITED STATES 4 Regional Cancer Center Stockholm–Gotland, Stockholm, Sweden 1 Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden 2 Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden 5 Karolinska University Laboratory, Karolinska University Hospital, Stockholm, Sweden 3 Center for Research and Development, Uppsala University, Region Gävleborg, Sweden |
AuthorAffiliation_xml | – name: 4 Regional Cancer Center Stockholm–Gotland, Stockholm, Sweden – name: Vanderbilt University School of Medicine, UNITED STATES – name: 2 Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden – name: 5 Karolinska University Laboratory, Karolinska University Hospital, Stockholm, Sweden – name: 1 Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden – name: 3 Center for Research and Development, Uppsala University, Region Gävleborg, Sweden |
Author_xml | – sequence: 1 givenname: Jiayao orcidid: 0000-0002-4718-1414 surname: Lei fullname: Lei, Jiayao organization: Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden – sequence: 2 givenname: Alexander surname: Ploner fullname: Ploner, Alexander organization: Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden – sequence: 3 givenname: Camilla surname: Lagheden fullname: Lagheden, Camilla organization: Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden – sequence: 4 givenname: Carina surname: Eklund fullname: Eklund, Carina organization: Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden – sequence: 5 givenname: Sara surname: Nordqvist Kleppe fullname: Nordqvist Kleppe, Sara organization: Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden – sequence: 6 givenname: Bengt orcidid: 0000-0003-3046-3447 surname: Andrae fullname: Andrae, Bengt organization: Center for Research and Development, Uppsala University, Region Gävleborg, Sweden – sequence: 7 givenname: K Miriam surname: Elfström fullname: Elfström, K Miriam organization: Regional Cancer Center Stockholm-Gotland, Stockholm, Sweden – sequence: 8 givenname: Joakim orcidid: 0000-0001-8588-6506 surname: Dillner fullname: Dillner, Joakim organization: Karolinska University Laboratory, Karolinska University Hospital, Stockholm, Sweden – sequence: 9 givenname: Pär orcidid: 0000-0002-5184-8971 surname: Sparén fullname: Sparén, Pär organization: Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden – sequence: 10 givenname: Karin orcidid: 0000-0002-6865-0224 surname: Sundström fullname: Sundström, Karin organization: Karolinska University Laboratory, Karolinska University Hospital, Stockholm, Sweden |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30273338$$D View this record in MEDLINE/PubMed https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-369507$$DView record from Swedish Publication Index http://kipublications.ki.se/Default.aspx?queryparsed=id:139490102$$DView record from Swedish Publication Index |
BookMark | eNp1Uttu1DAQjVARvcAfIIjECw9k8SWZxDwgrcqllSrxArxak9jZ9TZrp3ayVf8ep5tWXQSSrRmNzzlz8ZwmR9ZZnSSvKVlQXtKPGzd6i92i32q1oIQwAHiWnNAiFxmFEo6e-MfJaQibiBFEkBfJMSes5JxXJ8nmwqzWmTfhOl2PW7Rpj73pOrfFnfFjSMOAQzRoVdp7t7IumJAaG88Og9nptNF-Zxrs0gZt9D-ly9TiYJy9NSq-urXzQ1QZ1d3L5HmLXdCvZnuW_Pr29ef5RXb14_vl-fIqa4DyIasJaSrSFjltK8YUshw4FapiFdYMSga0IiXqWvFcITAGDNqS54WqW5ZXuuJnydu9bt-5IOcxBclYMYEJQERc7hHK4Ub23mzR30mHRt4HnF9J9INpOi0ZCk6rUkBdYw5NXnEolK5bUfIGoo1aYq8VbnU_1gdqcWJKzvFrM10ZtKRc5IJQwiL3w3-5X8zv5X0l4yg5iIKUEf55bmys46c32g4eu8OMBy_WrOXK7SRQAMGmvt_PAt7djDoMcmtCo7sOrXZjHBGlRVkwAVOud39B_z3IfI9qvAvB6_axGErktKUPLDltqZy3NNLePG3kkfSwlvwP4Vzpaw |
CitedBy_id | crossref_primary_10_3390_cells10030610 crossref_primary_10_1038_s41416_020_01111_0 crossref_primary_10_1186_s12935_020_01512_4 crossref_primary_10_1177_17588359211010939 crossref_primary_10_1002_bab_2258 crossref_primary_10_3390_jcm11144225 crossref_primary_10_1007_s40121_024_00952_z crossref_primary_10_1080_0284186X_2021_1979249 crossref_primary_10_1055_s_0043_1774709 crossref_primary_10_1158_1055_9965_EPI_19_1259 crossref_primary_10_1042_BSR20210670 crossref_primary_10_1097_LGT_0000000000000479 crossref_primary_10_5694_mja2_50477 crossref_primary_10_1155_2022_6499744 crossref_primary_10_1016_j_ygyno_2019_05_024 crossref_primary_10_3389_fonc_2020_01733 crossref_primary_10_3390_biology11070956 crossref_primary_10_1016_j_vacune_2023_10_001 crossref_primary_10_3390_jcm11164825 crossref_primary_10_3390_cancers11040511 crossref_primary_10_3389_fimmu_2022_907599 crossref_primary_10_3389_fgene_2021_747090 crossref_primary_10_1016_j_currproblcancer_2021_100764 crossref_primary_10_1136_ijgc_2020_001457 crossref_primary_10_1002_jmv_27020 crossref_primary_10_1002_1878_0261_13219 crossref_primary_10_1136_ijgc_2021_003014 crossref_primary_10_1158_0008_5472_CAN_19_0116 crossref_primary_10_1016_j_jasc_2019_03_005 crossref_primary_10_1016_j_ygyno_2019_04_680 crossref_primary_10_1088_1361_6560_ac4fa3 crossref_primary_10_1016_j_vacun_2023_05_001 crossref_primary_10_1200_JCO_21_01930 crossref_primary_10_1136_bmjopen_2020_039636 crossref_primary_10_1136_jclinpath_2021_208054 crossref_primary_10_1186_s12879_023_08942_1 crossref_primary_10_1056_NEJMoa1917338 crossref_primary_10_1155_2020_7046894 crossref_primary_10_1038_s41392_021_00787_x crossref_primary_10_2174_1871520620666200224093301 crossref_primary_10_1007_s00404_022_06415_5 crossref_primary_10_1002_cam4_4953 crossref_primary_10_1016_j_critrevonc_2020_103178 crossref_primary_10_1002_jmv_28410 crossref_primary_10_3390_v13071323 crossref_primary_10_1097_AOG_0000000000005370 crossref_primary_10_1007_s12011_022_03226_2 crossref_primary_10_1099_jgv_0_001374 crossref_primary_10_1038_s41416_020_01153_4 crossref_primary_10_1016_j_jasc_2020_08_006 crossref_primary_10_1136_bmj_l1207 |
Cites_doi | 10.1016/j.ejogrb.2013.06.027 10.1007/s00404-013-2803-2 10.1016/S1470-2045(10)70230-8 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F 10.1177/1536867X1501500112 10.1002/ijc.28902 10.1007/s10654-016-0117-y 10.1016/S0140-6736(13)62218-7 10.1016/j.ygyno.2012.01.012 10.1200/JCO.2007.11.2995 10.1093/jnci/djx225 10.1016/j.ygyno.2006.05.017 10.1159/000052925 10.1002/ijc.28188 10.1002/ijc.25396 10.1093/jnci/dji187 10.1016/j.ijrobp.2009.09.021 10.1136/bmj.e900 10.1002/(SICI)1096-9896(199703)181:3<253::AID-PATH755>3.0.CO;2-0 10.1016/j.ijgo.2009.02.012 10.1016/0140-6736(90)92693-C 10.1056/NEJMoa0912217 10.1002/ijc.23712 10.1056/NEJMe1003607 10.1016/j.jcv.2015.12.007 10.1016/j.jcv.2016.04.016 10.1136/bmj.320.7242.1102 10.1128/JCM.02007-08 |
ContentType | Journal Article |
Copyright | 2018 Lei et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2018 Lei et al 2018 Lei et al |
Copyright_xml | – notice: 2018 Lei et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2018 Lei et al 2018 Lei et al |
DBID | NPM AAYXX CITATION 3V. 7TK 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S M1P PIMPY PQEST PQQKQ PQUKI PRINS 7X8 5PM ACNBI ADTPV AOWAS D8T DF2 ZZAVC DOA CZK |
DOI | 10.1371/journal.pmed.1002666 |
DatabaseName | PubMed CrossRef ProQuest Central (Corporate) Neurosciences Abstracts ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials AUTh Library subscriptions: ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) Access via ProQuest (Open Access) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) SWEPUB Uppsala universitet full text SwePub SwePub Articles SWEPUB Freely available online SWEPUB Uppsala universitet SwePub Articles full text DOAJ Directory of Open Access Journals PLoS Medicine |
DatabaseTitle | PubMed CrossRef Publicly Available Content Database ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) Neurosciences Abstracts ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest Medical Library ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Central Korea ProQuest One Academic ProQuest Medical Library (Alumni) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic PubMed Publicly Available Content Database |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X7 name: ProQuest Health & Medical Collection url: https://search.proquest.com/healthcomplete sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
DocumentTitleAlternate | High-risk HPV and invasive cervical cancer prognosis |
EISSN | 1549-1676 |
Editor | Zheng, Wei |
Editor_xml | – sequence: 1 givenname: Wei surname: Zheng fullname: Zheng, Wei |
EndPage | e1002666 |
ExternalDocumentID | 2252262066 oai_doaj_org_article_2a9318796bba46c48365debf973c6ebf oai_prod_swepub_kib_ki_se_139490102 oai_DiVA_org_uu_369507 10_1371_journal_pmed_1002666 30273338 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GeographicLocations | Sweden |
GeographicLocations_xml | – name: Sweden |
GrantInformation_xml | – fundername: ; grantid: 140665 – fundername: ; grantid: 201507930001 – fundername: ; grantid: KF10-0046 – fundername: ; grantid: RB13-0011 – fundername: ; grantid: 2014-03732 – fundername: ; grantid: 2017-02346 – fundername: ; grantid: 110569 |
GroupedDBID | --- 123 29O 2WC 3V. 53G 5VS 7X7 88E 8FI 8FJ AAFWJ AAWTL ABDBF ABUWG ACGFO ACIHN ACPRK ADBBV ADRAZ AEAQA AENEX AFKRA AFPKN AFRAH AFXKF AHMBA AKRSQ ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS B0M BAWUL BCGST BCNDV BENPR BPHCQ BVXVI BWKFM CCPQU CS3 DIK DU5 E3Z EAP EAS EBD EBS EJD EMK EMOBN ESX F5P FPL FYUFA GROUPED_DOAJ GX1 H13 HMCUK HYE IAO ICW IHR IHW INH INR IOF IOV IPNFZ IPO ISN ISR ITC KQ8 M1P M48 MK0 M~E NPM O5R O5S OK1 P2P PIMPY PQQKQ PROAC PSQYO PV9 RIG RNS RPM RZL SV3 TR2 TUS UKHRP WOQ WOW XSB YZZ ~8M AAYXX CITATION 7TK 7XB 8FK AZQEC DWQXO K9. PQEST PQUKI PRINS 7X8 5PM ACNBI ADTPV AOWAS D8T DF2 ZZAVC AAPBV ABPTK CZK |
ID | FETCH-LOGICAL-c613t-b00c80f541f822da246319d828ab267261807aebd34da622626f7345dbf248e83 |
IEDL.DBID | RPM |
ISSN | 1549-1676 1549-1277 |
IngestDate | Sun Jun 04 13:13:08 EDT 2023 Thu Jul 04 21:07:42 EDT 2024 Sun Oct 06 03:39:19 EDT 2024 Fri Aug 23 23:59:57 EDT 2024 Tue Sep 17 21:17:37 EDT 2024 Fri Jun 28 12:32:03 EDT 2024 Tue Aug 20 11:32:43 EDT 2024 Fri Aug 23 00:37:49 EDT 2024 Sat Sep 28 08:37:29 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 10 |
Language | English |
License | This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Creative Commons Attribution License |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c613t-b00c80f541f822da246319d828ab267261807aebd34da622626f7345dbf248e83 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 I have read the journal's policy and the authors of this manuscript have the following competing interests: JD has obtained grants to his institution from Roche and Genomica for research on HPV tests. BA is supported by an unrestricted grant from the Swedish Strategic Research Fund, and BA is a member of the National Board of Health and Welfare Expert's Group in 2015 about HPV-based organised cervical screening. The other authors have no conflict of interest to declare. |
ORCID | 0000-0001-8588-6506 0000-0003-3046-3447 0000-0002-4718-1414 0000-0002-6865-0224 0000-0002-5184-8971 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6166926/ |
PMID | 30273338 |
PQID | 2252262066 |
PQPubID | 1436338 |
ParticipantIDs | plos_journals_2252262066 doaj_primary_oai_doaj_org_article_2a9318796bba46c48365debf973c6ebf swepub_primary_oai_prod_swepub_kib_ki_se_139490102 swepub_primary_oai_DiVA_org_uu_369507 pubmedcentral_primary_oai_pubmedcentral_nih_gov_6166926 proquest_miscellaneous_2115752967 proquest_journals_2252262066 crossref_primary_10_1371_journal_pmed_1002666 pubmed_primary_30273338 |
PublicationCentury | 2000 |
PublicationDate | 2018-10-01 |
PublicationDateYYYYMMDD | 2018-10-01 |
PublicationDate_xml | – month: 10 year: 2018 text: 2018-10-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: San Francisco – name: San Francisco, CA USA |
PublicationTitle | PLoS medicine |
PublicationTitleAlternate | PLoS Med |
PublicationYear | 2018 |
Publisher | Public Library of Science Public Library of Science (PLoS) |
Publisher_xml | – name: Public Library of Science – name: Public Library of Science (PLoS) |
References | ref12 V Galic (ref22) 2012; 125 B Andrae (ref23) 2012; 344 ref15 A Soderlund-Strand (ref14) 2009; 47 CH Lai (ref5) 2007; 25 CC Wang (ref8) 2010; 78 KK Ang (ref11) 2010; 363 DR Lowy (ref10) 2010; 363 JM Walboomers (ref1) 1999; 189 K Cuschieri (ref4) 2014; 135 PW Dickman (ref21) 2015; 15 CL Barreto (ref3) 2013; 288 M Kogevinas (ref32) 1997 AE Cavelaars (ref33) 2000; 320 G Riou (ref7) 1990; 335 K Andersson (ref17) 2013; 133 S de Sanjose (ref24) 2010; 11 C Lagheden (ref16) 2016; 80 ref20 WA Tjalma (ref18) 2013; 170 KW Lo (ref6) 2001; 51 N Li (ref25) 2011; 128 JF Ludvigsson (ref13) 2016; 31 S. Pecorelli (ref19) 2009; 105 M Hortlund (ref27) 2016; 75 L Dahlgren (ref9) 2006; 26 M Schiffman (ref26) 2018; 110 G Ronco (ref29) 2014; 383 JM Walboomers (ref30) 1997; 181 SK Kjaer (ref28) 2008; 123 MJ Khan (ref2) 2005; 97 SE Waggoner (ref31) 2006; 103 |
References_xml | – volume: 170 start-page: 45 issue: 1 year: 2013 ident: ref18 article-title: Cervical cancer screening: which HPV test should be used—L1 or E6/E7? publication-title: Eur J Obstet Gynecol Reprod Biol doi: 10.1016/j.ejogrb.2013.06.027 contributor: fullname: WA Tjalma – volume: 288 start-page: 643 issue: 3 year: 2013 ident: ref3 article-title: Detection of human papillomavirus in biopsies of patients with cervical cancer, and its association with prognosis publication-title: Arch Gynecol Obstet doi: 10.1007/s00404-013-2803-2 contributor: fullname: CL Barreto – volume: 11 start-page: 1048 issue: 11 year: 2010 ident: ref24 article-title: Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study publication-title: Lancet Oncol doi: 10.1016/S1470-2045(10)70230-8 contributor: fullname: S de Sanjose – volume: 189 start-page: 12 issue: 1 year: 1999 ident: ref1 article-title: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide publication-title: J Pathol doi: 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F contributor: fullname: JM Walboomers – start-page: 177 issue: 138 year: 1997 ident: ref32 article-title: Socioeconomic differences in cancer survival: a review of the evidence publication-title: IARC Sci Publ contributor: fullname: M Kogevinas – ident: ref20 – volume: 15 start-page: 186 issue: 1 year: 2015 ident: ref21 article-title: Estimating and modeling relative survival publication-title: Stata J. doi: 10.1177/1536867X1501500112 contributor: fullname: PW Dickman – volume: 135 start-page: 2721 issue: 11 year: 2014 ident: ref4 article-title: Influence of HPV type on prognosis in patients diagnosed with invasive cervical cancer publication-title: Int J Cancer doi: 10.1002/ijc.28902 contributor: fullname: K Cuschieri – volume: 31 start-page: 125 issue: 2 year: 2016 ident: ref13 article-title: Registers of the Swedish total population and their use in medical research publication-title: Eur J Epidemiol doi: 10.1007/s10654-016-0117-y contributor: fullname: JF Ludvigsson – volume: 383 start-page: 524 issue: 9916 year: 2014 ident: ref29 article-title: Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials publication-title: Lancet doi: 10.1016/S0140-6736(13)62218-7 contributor: fullname: G Ronco – volume: 125 start-page: 287 issue: 2 year: 2012 ident: ref22 article-title: Prognostic significance of adenocarcinoma histology in women with cervical cancer publication-title: Gynecol Oncol doi: 10.1016/j.ygyno.2012.01.012 contributor: fullname: V Galic – volume: 25 start-page: 3628 issue: 24 year: 2007 ident: ref5 article-title: Role of human papillomavirus genotype in prognosis of early-stage cervical cancer undergoing primary surgery publication-title: J Clin Oncol doi: 10.1200/JCO.2007.11.2995 contributor: fullname: CH Lai – volume: 110 start-page: 501 issue: 5 year: 2018 ident: ref26 article-title: Relative performance of HPV and cytology components of cotesting in cervical screening publication-title: J Natl Cancer Inst doi: 10.1093/jnci/djx225 contributor: fullname: M Schiffman – volume: 103 start-page: 853 issue: 3 year: 2006 ident: ref31 article-title: Association between cigarette smoking and prognosis in locally advanced cervical carcinoma treated with chemoradiation: a Gynecologic Oncology Group study publication-title: Gynecol Oncol doi: 10.1016/j.ygyno.2006.05.017 contributor: fullname: SE Waggoner – volume: 51 start-page: 202 issue: 3 year: 2001 ident: ref6 article-title: Clinical and prognostic significance of human papillomavirus in a Chinese population of cervical cancers publication-title: Gynecol Obstet Invest doi: 10.1159/000052925 contributor: fullname: KW Lo – volume: 133 start-page: 1840 issue: 8 year: 2013 ident: ref17 article-title: Prospective study of genital human papillomaviruses and nonmelanoma skin cancer publication-title: Int J Cancer doi: 10.1002/ijc.28188 contributor: fullname: K Andersson – volume: 128 start-page: 927 issue: 4 year: 2011 ident: ref25 article-title: Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication publication-title: Int J Cancer doi: 10.1002/ijc.25396 contributor: fullname: N Li – volume: 97 start-page: 1072 issue: 14 year: 2005 ident: ref2 article-title: The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice publication-title: J Natl Cancer Inst doi: 10.1093/jnci/dji187 contributor: fullname: MJ Khan – volume: 78 start-page: 1111 issue: 4 year: 2010 ident: ref8 article-title: Clinical effect of human papillomavirus genotypes in patients with cervical cancer undergoing primary radiotherapy publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/j.ijrobp.2009.09.021 contributor: fullname: CC Wang – ident: ref15 – volume: 344 start-page: e900 year: 2012 ident: ref23 article-title: Screening and cervical cancer cure: population based cohort study publication-title: BMJ doi: 10.1136/bmj.e900 contributor: fullname: B Andrae – volume: 181 start-page: 253 issue: 3 year: 1997 ident: ref30 article-title: Do HPV-negative cervical carcinomas exist publication-title: J Pathol doi: 10.1002/(SICI)1096-9896(199703)181:3<253::AID-PATH755>3.0.CO;2-0 contributor: fullname: JM Walboomers – volume: 105 start-page: 103 issue: 2 year: 2009 ident: ref19 article-title: Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium publication-title: Int J Gynaecol Obstet doi: 10.1016/j.ijgo.2009.02.012 contributor: fullname: S. Pecorelli – volume: 335 start-page: 1171 issue: 8699 year: 1990 ident: ref7 article-title: Association between poor prognosis in early-stage invasive cervical carcinomas and non-detection of HPV DNA publication-title: Lancet doi: 10.1016/0140-6736(90)92693-C contributor: fullname: G Riou – volume: 26 start-page: 829 issue: 2A year: 2006 ident: ref9 article-title: Differences in human papillomavirus type may influence clinical outcome in early stage cervical cancer publication-title: Anticancer Res contributor: fullname: L Dahlgren – volume: 363 start-page: 24 issue: 1 year: 2010 ident: ref11 article-title: Human papillomavirus and survival of patients with oropharyngeal cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa0912217 contributor: fullname: KK Ang – volume: 123 start-page: 1864 issue: 8 year: 2008 ident: ref28 article-title: Population-based prevalence, type- and age-specific distribution of HPV in women before introduction of an HPV-vaccination program in Denmark publication-title: Int J Cancer doi: 10.1002/ijc.23712 contributor: fullname: SK Kjaer – volume: 363 start-page: 82 issue: 1 year: 2010 ident: ref10 article-title: Prognostic implications of HPV in oropharyngeal cancer publication-title: N Engl J Med doi: 10.1056/NEJMe1003607 contributor: fullname: DR Lowy – volume: 75 start-page: 33 year: 2016 ident: ref27 article-title: Laboratory audit as part of the quality assessment of a primary HPV-screening program publication-title: J Clin Virol doi: 10.1016/j.jcv.2015.12.007 contributor: fullname: M Hortlund – volume: 80 start-page: 36 year: 2016 ident: ref16 article-title: Validation of a standardized extraction method for formalin-fixed paraffin-embedded tissue samples publication-title: J Clin Virol doi: 10.1016/j.jcv.2016.04.016 contributor: fullname: C Lagheden – volume: 320 start-page: 1102 issue: 7242 year: 2000 ident: ref33 article-title: Educational differences in smoking: international comparison publication-title: BMJ doi: 10.1136/bmj.320.7242.1102 contributor: fullname: AE Cavelaars – volume: 47 start-page: 541 issue: 3 year: 2009 ident: ref14 article-title: Modified general primer PCR system for sensitive detection of multiple types of oncogenic human papillomavirus publication-title: J Clin Microbiol doi: 10.1128/JCM.02007-08 contributor: fullname: A Soderlund-Strand – ident: ref12 |
SSID | ssj0029090 |
Score | 2.5327332 |
Snippet | High-risk human papillomavirus (hrHPV) infection is established as the major cause of invasive cervical cancer (ICC). However, whether hrHPV status in the... Background High-risk human papillomavirus (hrHPV) infection is established as the major cause of invasive cervical cancer (ICC). However, whether hrHPV status... BACKGROUNDHigh-risk human papillomavirus (hrHPV) infection is established as the major cause of invasive cervical cancer (ICC). However, whether hrHPV status... In a study of Swedish medical records and tissue archives, Jiayao Lei and colleagues examine the link between hrHPV positivity in cervical tumors and prognosis. Background: High-risk human papillomavirus (hrHPV) infection is established as the major cause of invasive cervical cancer (ICC). However, whether hrHPV status... BackgroundHigh-risk human papillomavirus (hrHPV) infection is established as the major cause of invasive cervical cancer (ICC). However, whether hrHPV status... Background High-risk human papillomavirus (hrHPV) infection is established as the major cause of invasive cervical cancer (ICC). However, whether hrHPV status... |
SourceID | plos doaj swepub pubmedcentral proquest crossref pubmed |
SourceType | Open Website Open Access Repository Aggregation Database Index Database |
StartPage | e1002666 |
SubjectTerms | Age Bioindicators Biology and life sciences Cervical cancer Cervix Cohort analysis Diagnosis Genotyping Gynecology Health risk assessment Health risks Human papillomavirus Invasiveness Laboratories Medicin och hälsovetenskap Medicine and Health Sciences Migration Mortality Obstetrics Paraffin Poisson density functions Population studies Prognosis Squamous cell carcinoma Studies Tumors |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3db9MwELfQHhAvCBiwwEBGgsewJP5KeOsG04Q0nhjam-XYjhYoSdU049_nzk4LEZV4mdQqUuzG9d3Zd5c7_46Qt9Zxw5TxqXTWp9xhkNBlWWpFVXqMINocDzhffpEXV_zztbj-q9QX5oRFeOBIuJPCVAwrYsu6NlxaXjIpnK-bSjEr4Rp231xsnanJ1aqy8HYF8cfSvFBqOjTHVH4y8ej9CrRNACCVASHxj1IK2P2Idbrsh31257_pkzOQ0aCYzh-Rh5NFSRdxJo_JPd89Ifcvp5j5IfmOqRwpppDTUJCPrsyqXS77n-a2XY8DxSNFcDGdo5is1fVDO9C2g8-twdx2asN2AkNYlJD1B7qg8RXir9ZBa38DFjwNMLVPydX5p69nF-lUYSG1oMY3WH3HllkjeN6AoeBMwSUsSQdemKkLqcC7KjNgZO0Yd0aCpVbIRjEuXN0UvPQle0YOur7zR4SC2s9rD0YwuLfcZLnhgjdKGOaFaGrBE5JuSaxXEUhDh2iaAgckUkojS_TEkoScIh92fREGO9wA4dCTcOj_CUdCjpCL2wEGDbsXziLD5x9vObu_-c2uGRYcRlFM5_sR-iA8EUarVUKeR0HY_UkMAjNw-hOiZiIym8W8pWtvAqi3zKWsChj3XRSm2U8-tt8WYeLjqJmswIZPSLGnHypdPd3_0eJXDx5oXHHMwile3AVNX5IHYDRGTOD8mBxs1qN_BYbZpn4d1uBvxE05BQ priority: 102 providerName: Directory of Open Access Journals – databaseName: AUTh Library subscriptions: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3di9QwEA_nHYgv4vdVT4mgj3XbJk1aX2RP71iEO0Q8ubeQJulddW3rdnv--86k7R6Li9BSaFLSZCaZmczkN4S8MZZrJrULhTUu5BadhDaKQpPmmUMPoonxgPPZuVhc8M-X6eUeWUxnYTCscloT_UJtG4N75DPguwTB04WY6QJ3Acx69qH9HWL-KPSzjsk07pCDJObosD04Pjn_8nVjfOWR329BRLIwTqQcj9ExGc9Gqr1rQf54SFLhMRNvxZRH80f002XT7dJE_w2o3IId9aLq9AG5P-qYdD4wxUOy5-pH5O7Z6EV_TH5gcEeIQeXUp-ijrW6r5bL5pW-qVd9RPGQED11biuFbddNVHa1quG40RrtT4xcYaMIgz6ze0zkdNhX_VBZKm2vQ6akHrn1CLk5Pvn1chGPOhdCAYF9jPh6TRWXK4xJUB6sTLmCSWrDLdJEICfZWFgFpC8u41QIpIkrJeGqLMuGZy9hTsl83tTskFBSBuHCgFoPBy3UUa57yUqaauTQti5QHJJyGWLUDtIby_jUJJskwUgpJokaSBOQY6bCpi8DY_kWzulLjPFOJzhkmUBdFobkwPGMita4oc8mMgGdADpGKUwOduuWrgBxNlN1d_HpTDFMQ_Sq6dk0PdRCwCP3XMiDPBkbY_CS6hRljWUDkFots9WK7pK6uPcy3iIXIE2j37cBMW598qr7Pfcf7XjGRg1YfkGRHPRTDanz_s8JbdQ7GOOcYl5M8_3-fX5B7oCAO-L_xEdlfr3r3EpSwdfFqnF9_AQpmNPU priority: 102 providerName: ProQuest – databaseName: Scholars Portal Journals (Open Access) dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3dj5QwEG_OMzG-GL-P8zQ10Ucu0JYWTIxZPy4Xk_XJNffWFFo8dIU9WE79750psAlxfTPZDQktlM5MmRlm-htCXhRWGK6MC6UtXCgsBgltFIVFkqUOI4hFjBucl5_k-Up8vEguDshUs3UkYLfXtcN6Uqt2ffrr6vcbWPCvfdUGFU8XnW5Af3hIUTDJb5CbTHCBMr8Uu7gCyyL_1QVxycKYKTVupvvXXWbKymP6Iwbquun22aN_p1XOwEe9wjq7S-6MliZdDKJxjxy4-j65tRxj6Q_IN0zxCDG1nPpCfXRjNtV63fww11XbdxS3GsHB1JZiElfddFVHqxp-1wZz3mnhXzMwRIGS076iCzp8WvxZWWhtLoGo1MPXPiSrsw-f352HY-WFsAD1vsWqPEUalYmISzAgrGFCwlK14J2ZnEkFXlcaAYNzy4U1Eiw4JkvFRWLzkonUpfwROayb2h0RCuZAnDswjsHtFSaKjUhEqRLDXZKUeSICEk4k1psBYEP7KJsCx2SglEaW6JElAXmLfNj1RXhsf6Jpv-pxtWlmMo5l1GWeGyELkXKZWJeXmeKFhGNAjpCL0wCdhrcaziLC-59MnN3f_HzXDAsRoyumdk0PfRC2CKPYKiCPB0HYPSQGhznnaUDUTERms5i31NWlB_uWsZQZg3FfDsI0u-R99WXhJ973mssMbPuAsD39UBnr8fz3Cv-6c0DjTGB2Djv-HzR9Qm6DMTlgBccn5HDb9u4pGGzb_Jlfg38AvAFDAw priority: 102 providerName: Scholars Portal |
Title | High-risk human papillomavirus status and prognosis in invasive cervical cancer: A nationwide cohort study |
URI | https://www.ncbi.nlm.nih.gov/pubmed/30273338 https://www.proquest.com/docview/2252262066/abstract/ https://search.proquest.com/docview/2115752967 https://pubmed.ncbi.nlm.nih.gov/PMC6166926 https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-369507 http://kipublications.ki.se/Default.aspx?queryparsed=id:139490102 https://doaj.org/article/2a9318796bba46c48365debf973c6ebf http://dx.doi.org/10.1371/journal.pmed.1002666 |
Volume | 15 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db5swELfaTqr6Mu27bF3EpO2RBPAX7C3tWlWbUnXTOuUNGdu0bAlEIen-_d0ZiBo1T5MSI2En2L4zd-e7-5mQj9owRaWygTDaBsygk9CEYaB5mlj0IOoIE5wnV-Lyhn2d8uke4X0ujAva13k5rGbzYVXeudjKxVyP-jix0fXkTERCpLEY7ZN9SWlvondWVhq6jRWEHguiWMouX47KaNSRZ7gAQeOwR0F3PyKH6LqjFDNUHogmh-CPiKezutmlfT4OotyCGnXi6eIZedrplf647f9zsmerF-Rw0nnOX5LfGNARYCC5747l8xdqUc5m9Vzdl8t142NiEVxUZXwM2arqpmz8soLPvcIId1-7lwo8QiOfLD_7Y7_dSPxbGqit70CP9x1Y7Styc3H-8-wy6M5ZCDQI8xWewaOTsOAsKkBdMCpmAhamAVtM5bGQYGMlIZAzN5QZJUBfi0UhKeMmL2KW2IS-JgdVXdlj4oPwj3ILqjAYuUyFkWKcFZIrajkvcs48EvRTnC1aOI3M-dQkmCHtTGVInayjjkdOkQ6btgiG7W7Uy9usY4ksVinFQ9NFnismNEuo4MbmRSqpFnD1yDFSsX9Ak8E7DEcR4v-f9JTdXf1hUw3LDn0pqrL1GtogSBH6rKVH3rSMsOlkz08ekVsssjWK7RrgdAft3XG2Rz61zLT1ky_lr7Eb-HqdUZGCJu-ReEc7FL1Zd_9Pid-ssTDHKcNYnPjtf3frHTkCfbGFA45OyMFqubbvQSdb5QNYiVM5IE9Oz6-ufwzczgaU374nUE4YlrBG_wErSD4q |
link.rule.ids | 230,315,733,786,790,870,891,2115,2236,12083,21416,24346,27957,27958,31754,31755,33779,33780,43345,43840,53827,53829,74102,74659 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwELegk4AXxOeWMcBI8BiWxI6T8II62FRgrRDa0N4sx3ZYoEtK045_nzvH7VRRISWKFDty7Dv77nzn3xHyWhuuWKZsKIy2ITfoJDRRFOq0yC16EHWMB5zHEzE6558v0gu_4db5sMrVmugWatNq3CM_BL5LEDxdiPez3yFmjULvqk-hcZvscAamyoDsHB1Pvn5bm1xF5HZZEIcsjJMs84fnWBYfelq9nYHUcUCkwiEl3ggnh-GPmKfTttumf_4bRrkBNuoE1MkDct9rlnTYs8JDcss2j8idsfedPyY_MaQjxFBy6hLz0Zma1dNpe6Wu6_myo3i0CB6qMRSDtpq2qztaN3BdK4xxp9otK9CERk6Zv6ND2m8l_qkNlLaXoMlTB1f7hJyfHJ99GIU-00KoQZwvMAuPzqMq5XEFCoNRCRcwNQ1YY6pMRAZWVh4BQUvDuFEC6SCqjPHUlFXCc5uzp2TQtI3dIxTEf1xaUIbBzOUqihVPeZWlitk0rcqUByRcDbGc9YAa0nnVMjBE-pGSSBLpSRKQI6TDui7CYbsX7fyH9LNLJqpgmDZdlKXiQvOcidTYsioypgU8A7KHVFw10MkbbgrIwYqy24tfrYth4qE3RTW2XUIdhClCr3UWkN2eEdY_ic5gBsZ_QLINFtnoxWZJU186cG8RC1Ek0O6bnpk2PvlYfx-6ji-XkokCdPmAJFvqofCV_v2vGm_ZWRjjgmM0TrL__z6_JHdHZ-NTefpp8uUZuQcqYo8AHB-QwWK-tM9BDVuUL_xc-wtArDQo |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwELdgSBMviO8FBhgJHkOT2LETXlBhVONjEw8M9c1ybIcFSlKadvz73Dluq4oKqVWk2JVr353vznf-HSEvjOWaSe1iYY2LucUgoU2S2ORl4TCCaFK84Hx2Lk4v-MdpPg35T31Iq1zviX6jtp3BM_IR8F2G4OlCjOqQFvHlZPJm_jvGClIYaQ3lNK6TG6AlE6xmIKdb56tM_HkLIpLFaSZluEbHZDoKVHs1B_3jIUmFx0zcqimP5o_op7Ou32eJ_ptQuQM76lXV5Da5FWxMOh6Y4g655tq75PAsRNHvkR-Y3BFjUjn1JfroXM-b2az7pa-axaqneMkIHrq1FNO32q5vetq08LnSmO1Ojd9gYAiDPLN4Tcd0OFT801ho7S7BpqceuPY-uZi8__ruNA41F2IDin2J9XhMkdQ5T2swHazOuAAhteCX6SoTEvytIgHSVpZxqwVSRNSS8dxWdcYLV7AH5KDtWndEKBgCaeXALAaHl-sk1Tzntcw1c3leVzmPSLxeYjUfoDWUj69JcEmGlVJIEhVIEpG3SIdNXwTG9i-6xXcV5ExlumRYQF1UlebC8IKJ3LqqLiUzAp4ROUIqrgfo1ZavInK8puz-5uebZhBBjKvo1nUr6IOARRi_lhF5ODDC5k9iWJgxVkRE7rDIzix2W9rm0sN8i1SIMoNxXw7MtPOTk-bb2E98tVJMlGDVRyTb0w_VsArvfzb4Vb2DNS455uVkj_4_52fkEIRMff5w_ukxuQm24gAFnB6Tg-Vi5Z6APbasnnpB-wtpMTbu |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=High-risk+human+papillomavirus+status+and+prognosis+in+invasive+cervical+cancer%3A+A+nationwide+cohort+study&rft.jtitle=PLoS+medicine&rft.au=Jiayao+Lei&rft.au=Alexander+Ploner&rft.au=Camilla+Lagheden&rft.au=Carina+Eklund&rft.date=2018-10-01&rft.pub=Public+Library+of+Science+%28PLoS%29&rft.issn=1549-1277&rft.eissn=1549-1676&rft.volume=15&rft.issue=10&rft.spage=e1002666&rft_id=info:doi/10.1371%2Fjournal.pmed.1002666&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_2a9318796bba46c48365debf973c6ebf |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1549-1676&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1549-1676&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1549-1676&client=summon |